

Propanc Biopharma reports strong preclinical data from pancreatic cancer drug, PRP, showing over 90% tumor inhibition and extended survival.
You can purchase shares of Propanc Biopharma (NASDAQ:PPCB) through any online brokerage.
Other companies in Propanc Biopharma’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
There is no analysis for Propanc Biopharma to provide a consensus price target.
The stock price for Propanc Biopharma (NASDAQ: PPCB) is $1.81 last updated November 5, 2026 at 8:09 AM EST.
There are no upcoming dividends for Propanc Biopharma.
Propanc Biopharma does not have any upcoming earnings scheduled.
There is no upcoming split for Propanc Biopharma.
Propanc Biopharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the...